摘要
目的探索妥洛特罗贴剂佐治儿童复合病因慢性咳嗽的临床研究,以及对哪种复合病因慢性咳嗽效果最好,为指导合理治疗复合病因儿童慢性咳嗽提供治疗思路和依据。方法选取2014年7月~2016年1月我院儿童慢性咳嗽门诊复合病因慢性咳嗽患儿128例,根据慢性咳嗽的不同病因随机分为治疗组(67例)和对照组(61例),其中治疗组包括咳嗽变异性哮喘合并上气道咳嗽综合征23例(A1组),上气道咳嗽综合征26例(B1组)、咳嗽变异性哮喘18例(C1组),对照组包括咳嗽变异性哮喘合并上气道咳嗽综合征20例(A2组),上气道咳嗽综合征24例(B2组)、咳嗽变异性哮喘17例(C2组),治疗组和对照组患儿均给予统一的扩张支气管、抗过敏、抗感染治疗、祛痰药进行治疗,而治疗组加用妥洛特罗贴治疗。比较治疗组与对照组治疗后的临床疗效、肺功能指标(PEF和PEFR)、咳嗽症状评分及喘息发作次数、呼吸道感染次数的变化情况,以及治疗组不同疾病类型的临床疗效,并对用药安全性进行观察。结果治疗后,治疗组临床总有效率达89.55%,显著高于对照组(P<0.05);治疗组肺功能指标PEF较治疗前及对照组显著升高,而PEFR较治疗前及对照组明显降低,差异具有显著性(P<0.05);治疗组患儿咳嗽症状评分及喘息发作次数、呼吸道感染次数治疗后明显降低且显著低于对照组,组间对比分析显示差异具有显著性(P<0.05)。对治疗组不同复合病因疾病患儿治疗后的临床疗效进行比较,结果显示,C1组治疗后的总有效率最高,达94.44%,均显著高于A1组、B1组。C1组患儿的PEF升高最显著,PEFR也显著低于其他两组(P<0.05)。且两组患儿治疗过程中均未出现皮疹、头痛、恶心等明显异常。结论妥洛特罗贴剂对慢性咳嗽治疗效果有效,尤其对单纯性咳嗽变异性哮喘效果良好,其它合并病效果欠佳,咳嗽变异性哮喘合并上气道咳嗽综合征引致的慢性�
Objective To investigate the clinical feasibility of Tulobuterol Patch in treatment of children chronic cough caused by complex etiology, to explore its best effect for what kind of complex causes chronic cough, and to provide guidance for treatment of chronic cough in children with complex etiology. Methods 128 cases of children chronic cough caused by different causes cured in our hospital outpatient clinic from July 2014 to January 2016 were selected as the study objects. They were randomly divided into treatment group （67 cases） and control group （61 cases）, accoreding to the different causes of chronic cough. The treatement group included 23 cases of cough variant asthma complicate with upper airway cough syndrome （group A1）. 26 cases of upper airway cough syndrome （group B 1）, 18 cases of cough variant asthma （group C 1）. The control group included 20 cases of cough variant asthma complicate with upper airway cough syndrome （group A2）, 24 cases of upper airway cough syndrome （group B2） and 17 cases of cough variant asthma （group C2）. All children of treatment group and control group were treated with the unity of bronchiectasis, anti allergic, anti infection treatment, expectorant treatment. And Tulohuterol Patehs were used in the treatment group.Clinical effect, Pulmonary function indices （PEF,PEFR）, cough symptom scores and wheezing episodes times, change of respiratory tract infection, clinical efficacy of different disease types in the treatment group of the two groups before and after the treatement were compared. And drug safety the two groups were observed. Results After the treatment, the total effective rate was 89.55 % in the observation group, which was significant （P 〈 0.05） higher than that in the control group. After treatment, the value of PEF in the observation group was elevated significantly than that of before and the control group, the value of PEFR was declined significantly in the observation group than that of before and the control group （P
出处
《中国医药科学》
2017年第2期7-11,共5页
China Medicine And Pharmacy
基金
广东省东莞市医疗卫生科技计划项目(2014105101201)
